U.S. Markets closed

Fortress Biotech, Inc. (FBIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.0000-0.0400 (-1.32%)
At close: 4:00PM EDT
3.0300 +0.03 (+1.00%)
After hours: 06:34PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.0400
Bid2.9600 x 2900
Ask3.0100 x 3000
Day's Range2.9500 - 3.0200
52 Week Range2.1200 - 6.1000
Avg. Volume558,101
Market Cap291.958M
Beta (5Y Monthly)2.44
PE Ratio (TTM)N/A
EPS (TTM)-0.5630
Earnings DateNov 08, 2021 - Nov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.17
  • GlobeNewswire

    Fortress Biotech to Participate in Dawson James Securities’ 6th Annual Small Cap Growth Conference

    NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate update at Dawson James Securities’ 6th Annual Small Cap Growth Conference on Thursday, October 2

  • Benzinga

    18 Stocks Moving in Thursday's Pre-Market Session

    Gainers TSR, Inc. (NASDAQ: TSRI) rose 40.2% to $12.89 in pre-market trading after the company reported record revenue for its first quarter. Cemtrex, Inc. (NASDAQ: CETX) rose 34.3% to $1.39 in pre-market trading after jumping 15% on Wednesday. KORE Wireless Group, Inc. (NYSE: KORE) rose 25.8% to $7.95 in pre-market trading. Esports Entertainment Group, Inc. (NASDAQ: GMBL) rose 16.2% to $7.69 in pre-market trading after the company posted Q4 results and issued FY22 sales guidance above estimates.

  • PR Newswire

    Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition

    Cyprium Therapeutics, Inc. ("Cyprium"), a Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") partner company, with support from its licensing partner Sentynl Therapeutics, Inc. ("Sentynl"), a wholly owned subsidiary of Cadila Healthcare Limited ("Zydus"), today announced positive results from an efficacy and safety analysis of data integrated from two completed pivotal studies in patients with Menkes disease treated with CUTX-101, copper histidinate (CuHis). In both pre-specified primary and sec